SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Q3 Interim Management Statement

7 Nov 2014 07:00

RNS Number : 4101W
Rentokil Initial PLC
07 November 2014
 



 

 

RENTOKIL INITIAL PLC (RTO)

INTERIM MANAGEMENT STATEMENT

7 November 2014

 

 (£m)

Q3 2014

Growth

YTD 2014

Growth

AER

AER

CER

AER

AER

CER

Revenue

439.5

(3.4%)

3.3%

1,293.9

(4.1%)

2.1%

Revenue - ongoing operations1

439.5

(2.9%)

3.8%

1,293.0

(3.2%)

3.1%

Adjusted operating profit2

62.6

(4.1%)

4.0%

162.8

(1.9%)

6.2%

Adjusted profit before tax2

53.5

5.7%

15.4%

131.0

3.6%

14.1%

Profit before tax

48.8

16.7%

27.0%

115.6

28.4%

42.0%

 

Revenue (at CER)Overall, revenue from ongoing operations increased by 3.8% in Q3 in line with Q2. Revenue grew organically by 1.1% and by 2.7% from businesses acquired in the last 12 months. Growth in Q3 in the Emerging (22.4%) and Growth (6.1%) quadrants was strong, partially offset by slight declines in the Protect and Enhance (-0.1%) and Manage for Value (-0.8%) quadrants. Divestments in the Manage for Value quadrant of our Belgian Flat Linen business and our Korean JV in 2013, and our Spanish Medical business in H1 2014, reduced revenue growth by 0.5% in Q3, resulting in total revenue growth in the quarter of 3.3%.

Profit (at CER)Adjusted operating profit increased by 4.0% in Q3, reflecting growth in North America, Pacific and Germany, as well as lower overheads, partly offset by lower profits in Benelux and slower growth in France.

Adjusted profit before tax at actual exchange rates continues to be negatively impacted by the continued strengthening of Sterling. Based on current exchange rates the impact of currency movements would be around £17m for the full year, in line with our previous guidance.

Reorganisation costs and one-off items for continuing operations were significantly lower in Q3 at £0.1m versus £5.5m last year, contributing to an increase in profit before tax of 27.0% in the quarter. After taking into account currency movements, profit before tax at AER increased by 16.7%. We now expect reorganisation costs and one-off items to be less than £10m for the year.

Cash flow and interest costsOperating and free cash flow continue to be strong and we remain on track to achieve our targets for the year. During the quarter we took advantage of an invoice factoring exercise in our French business which is anticipated to increase working capital inflows by approximately £15m. With our improved net debt position we now expect interest costs to be in the region of £47m (at CER) for the year compared to the previous guidance of £50m.

M&AWe acquired 5 businesses in the quarter and have now acquired 18 businesses in pest control in the year along with one small acquisition in hygiene and three in plants. Combined annual revenues of the above businesses totalled £40m in the 12 months immediately prior to acquisition.

Commenting on the Q3 results Andy Ransom, CEO of Rentokil Initial plc, said:

"I am pleased to report that the business maintained the recent level of revenue growth in the quarter with the Pest Control category continuing to perform well in our Emerging and Growth quadrants. Challenging trading conditions persist in our European businesses, impacting our hygiene and workwear categories in our Protect & Enhance and Manage for Value quadrants.

"Profit growth in the quarter continues to reflect the benefit of more efficient businesses and reduced overheads and has been achieved despite the challenging European trading conditions. We continue to execute our strategy at pace, to drive improved revenue, profit and cash, and we expect Q4 operating performance to be in line with Q3."

 

 

Enquiries:

 

Investors / Analysts: Guy Smith Rentokil Initial plc 01276 536585/07879 662664

 

Media: Malcolm Padley Rentokil Initial plc 07788 978 199

Justine McIllroy Brunswick Group 020 7404 5959

Nina Coad

Oliver Hughes

 

A call for investors and analysts will be held on Friday 7 November at 9.15am:

 

Participant Details:

 

London, UK: +44(0)203 427 1912

Paris, France: +33(0)1 76 77 22 20

Hong Kong: +852 3002 1615

New York, USA: +1 646 254 3362

Participant PIN code: 7321731#

 

Playback Details (available for 14 days):

 

London, UK: +44(0)203 427 0598

Paris, France: +33(0)1 74 20 28 00

Hong Kong: +852 3011 4669

New York, USA: +1 347 366 9565

Playback PIN code: 7321731#

 

 

 

AER - actual exchange rates; CER - constant 2013 exchange rates

 

1ongoing revenue represents revenue with disposals removed and includes revenue from acquisitions.

2 before amortisation and impairment of intangibles (excluding computer software), reorganisation costs and one-off items, and net interest credit from pensions

 

This announcement contains statements that are, or may be, forward-looking regarding the group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUNRWRSBAARAA
Date   Source Headline
28th Jul 20253:00 pmRNSHolding(s) in Company
10th Jul 202511:00 amRNSHolding(s) in Company
1st Jul 202510:25 amRNSTotal Voting Rights
10th Jun 202510:05 amRNSAdditional Listing
3rd Jun 20254:00 pmRNSDirector/PDMR Shareholding
28th May 20257:00 amRNSSale of France Workwear
19th May 20252:30 pmRNSDirector/PDMR Shareholding
7th May 20254:15 pmRNSResult of AGM
7th May 20257:01 amRNSDirectorate Change: Appointment of NEDs
7th May 20257:00 amRNSDirectorate Change: Chief Executive to retire
28th Apr 20252:30 pmRNSIssue of Debt
17th Apr 20252:20 pmRNSHolding(s) in Company
17th Apr 20257:00 amRNSQ1 Trading Update
9th Apr 202510:25 amRNSHolding(s) in Company
1st Apr 20252:15 pmRNSNotice of Q1 Trading Update and Management Call
1st Apr 202510:25 amRNSBlock listing Interim Review
27th Mar 202510:25 amRNSDirector/PDMR Shareholding
26th Mar 202510:30 amRNSAnnual Financial Report
14th Mar 202510:00 amRNSDirector/PDMR Shareholding
6th Mar 20257:00 amRNSFinal Results
28th Jan 20257:00 amRNSTrading Update (unaudited)
14th Jan 202511:15 amRNSHolding(s) in Company
13th Jan 202511:15 amRNSHolding(s) in Company
13th Dec 20249:30 amRNSDirector/PDMR Shareholding
25th Nov 20247:00 amRNSDirectorate Change
12th Nov 202410:30 amRNSHolding(s) in Company
8th Nov 202410:30 amRNSHolding(s) in Company
17th Oct 20247:00 amRNSQ3 Trading Update
1st Oct 20242:00 pmRNSBlock listing Interim Review
25th Sep 20247:00 amRNSAppointment of Non-Executive Director
19th Sep 202410:30 amRNSDirector/PDMR Shareholding
11th Sep 20247:00 amRNSTrading Update
10th Sep 202410:30 amRNSHolding(s) in Company
5th Sep 202411:08 amRNSHolding(s) in Company
25th Jul 20247:00 amRNS2024 Interim Results
10th Jul 20244:35 pmRNSHolding(s) in Company
26th Jun 20245:12 pmRNSDirector/PDMR Shareholding
26th Jun 202411:08 amRNSHolding(s) in Company
17th May 20243:30 pmRNSDirector/PDMR Shareholding
8th May 20242:00 pmRNSResult of AGM
29th Apr 20243:00 pmRNSHolding(s) in Company
23rd Apr 20249:30 amRNSHolding(s) in Company
18th Apr 20247:00 amRNSQ1 Trading Update
2nd Apr 20241:28 pmRNSBlock listing Interim Review
2nd Apr 202412:17 pmRNSTotal Voting Rights
27th Mar 202410:23 amRNSAnnual Financial Report
19th Mar 20242:05 pmRNSAdditional Listing
14th Mar 202410:19 amRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSFinal Results
1st Dec 20237:00 amRNSNorth American Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.